Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Fineline Cube Apr 28, 2026
Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026
Company Deals

Fosun Pharma Partners with Soong Ching Ling Foundation for Women and Children’s Health

Fineline Cube Nov 7, 2022

The 5th China International Import Expo (CIIE) saw Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:...

Company Deals

Jumpcan Partners with Newsoara for PDE4 and Protease Inhibitors in China

Fineline Cube Nov 7, 2022

China-based Jumpcan Pharmaceutical (SHA: 600566) has announced a partnership with compatriot firm Newsoara BioPharma Co.,...

Company

Novo Nordisk to Invest RMB 400M in Shanghai at CIIE

Fineline Cube Nov 7, 2022

Novo Nordisk (NYSE: NVO) has announced at the 5th China International Import Expo (CIIE) an...

Company Drug

Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection

Fineline Cube Nov 7, 2022

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the...

Company Drug

Betta Pharmaceuticals’ BPI-452080 Accepted for Review by NMPA

Fineline Cube Nov 7, 2022

China’s Betta Pharmaceuticals (SHE: 300558) has announced that a clinical trial filing for its Category...

Company Drug

Qilu Regor’s RGT-264 Phosphate Tablets Approved for Phase I Study

Fineline Cube Nov 4, 2022

China-based biotech Qilu Regor Therapeutics Inc has announced receiving approval from the National Medical Products...

Company Deals

Hainan Free Trade Port to Simplify Drug Import Procedures

Fineline Cube Nov 4, 2022

The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September...

Policy / Regulatory

Hainan Free Trade Port to Simplify Drug Import Procedures

Fineline Cube Nov 4, 2022

The “Provisions on Facilitation of Drug Import in Hainan Free Trade Port,” released in September...

Company Drug

Sinovac’s Varicella Vaccine Receives WHO Pre-Qualification

Fineline Cube Nov 4, 2022

China-based Sinovac has announced receiving pre-qualification (PQ) status from the World Health Organization (WHO) for...

Company Drug

Reforgene Medicine RM-001 Thalassemia Gene Editing

Fineline Cube Nov 4, 2022

China-based Guangzhou Reforgene Medicine Co., Ltd’s in-house developed β-thalassemia gene editing drug RM-001 (HBG gene...

Company Drug

Walvax Biotech Launches Phase IIIb Trial for mRNA COVID-19 Vaccine

Fineline Cube Nov 4, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the initiation of a Phase IIIb...

Company Drug

Guangdong Zhongsheng Initiates Phase III Study for RAY1216 in COVID-19

Fineline Cube Nov 4, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the initiation of a randomized,...

Company

Bloomage Biotech CEO Investigated Over Discounted Share Sales

Fineline Cube Nov 4, 2022

The chairwoman of Chinese medical aesthetics player Bloomage Biotech Corp., Ltd (SHA: 688363), Ms. Zhao...

Policy / Regulatory

NMPA Proposes ‘Drug Online Sales Blacklist’ for Public Feedback

Fineline Cube Nov 4, 2022

The National Medical Products Administration (NMPA) has released a draft proposal for a “Drug Online...

Company Drug

Ascentage Pharma Announces Clinical Advances for Olverembatinib at ASH

Fineline Cube Nov 4, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced the latest clinical development of its olverembatinib (HQP1351), a...

Company Drug

Abbisko Enrolls First Patient in Phase II Study for ABSK091 in Urothelial Carcinoma

Fineline Cube Nov 4, 2022

China-based Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the enrollment of the first patient...

Company Drug

Blue Shield Pharma’s LD013 CAR-T Therapy Approved for Clinical Trials

Fineline Cube Nov 4, 2022

China-based Blue Shield Biotech’s in-house developed LD013, an autologous chimeric antigen receptor (CAR)-T cell therapy,...

Company Deals

Biomed Union Raises RMB 200M in Series B Round for Diagnostic Products

Fineline Cube Nov 4, 2022

Biomed Union (formerly known as Shanghai Biomed-union Biotechnology Co., Ltd), a tumor molecular diagnostic technology...

Company Deals

Yaguo Technology Secures Series A+ Funding for Airway Management Devices

Fineline Cube Nov 4, 2022

Yaguo Technology Co., Ltd, an airway management and respiratory therapy device maker based in Beijing,...

Company Deals

Novatim Immune Therapeutics Raises RMB 500M in First Financing Round

Fineline Cube Nov 4, 2022

China-based tumor immunotherapy developer Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has reportedly raised close to...

Posts pagination

1 … 598 599 600 … 658

Recent updates

  • Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
  • Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
  • AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.